石药集团(01093)绩后跌超6%，截至发稿，跌4.66%，报7.36港元，成交额2.11亿港元。 消息面上，石药集团发布前三季度业绩，期内收入198.91亿元人民币，同比减少12.32%；公司拥有人应 占溢利35.11亿元，同比减少7.06%，业绩显示，前三季度成药业务实现收入154.50亿元，同比减少 17.2%，主要是由于药品集中带量采购及国家医保药品目录内药品的价格调整等行业政策的持续影响所 致。 ...

消息面上，石药集团发布前三季度业绩，期内收入198.91亿元人民币，同比减少12.32%；公司拥有人应 占溢利35.11亿元，同比减少7.06%，业绩显示，前三季度成药业务实现收入154.50亿元，同比减少 17.2%，主要是由于药品集中带量采购及国家医保药品目录内药品的价格调整等行业政策的持续影响所 致。 智通财经APP获悉，石药集团(01093)绩后跌超6%，截至发稿，跌4.66%，报7.36港元，成交额2.11亿港 元。 ...

本集团坚持以创新为先并持续加大创新研发投入，着力加速创新研发管线兑现，进一步夯实并提升整体 产品管线的长期竞争优势。围绕"创新+国际化"双轮驱动战略，本集团依托丰富的创新资产，通过对外 授权、自主开发及研发合作等多元化模式，继续稳步推进国际化布局。 智通财经APP讯，石药集团(01093)发布截至2025年9月30日止9个月业绩，该集团取得收入人民币198.91 亿元(单位下同)，同比减少12.32%;公司拥有人应占溢利35.11亿元，同比减少7.06%;每股盈利30.72分。 成药业务于2025年首9个月实现收入154.50亿元(包括授权费收入15.40 亿元)，较去年同期减少17.2%，主 要是由于药品集中带量采购及国家医保药品目录内药品的价格调整等行业政策的持续影响所致。 于2025年首9个月，原料产品业务取得销售收入30.06亿元，较去年同期增加 10.3%。 维生素C产品于2025年首9个月的销售收入为17.88亿元，较去年同期增加 22.3%，主要是因为海外市场 需求有较大幅度增加，带动销售收入上涨。本集团未来将专注于产品质量，继续布局海外销售网络，进 一步提高市场份额。 ...

Group 1 - The company reported a sales revenue of approximately 1.976 billion RMB for the first half of 2025, representing a year-on-year decline of about 35% [1] - In HKD terms, the sales revenue for the first half of this year was approximately 2.147 billion HKD, also reflecting a year-on-year decrease of about 36% [1] - The net profit for the company was approximately 284 million HKD, which is a year-on-year decline of 58.7% [1] Group 2 - The total gross profit recorded by the group was 890 million HKD, down from 1.843 billion HKD in the same period last year [1] - The overall gross margin decreased by 13.7 percentage points from 55.2% in the previous year to 41.5% [1] - The decline in average selling prices of existing intravenous and ampoule injection products, along with a higher proportion of revenue from centralized procurement sales, contributed to the changes in gross profit and margin [1]

Core Viewpoint - The report from CMB International raises the target price for CSPC Pharmaceutical Group (01093) to HKD 9.3 while maintaining a "Neutral" rating, reflecting adjustments in revenue forecasts due to sales pressures on core products [1] Financial Performance - The revenue forecasts for 2025-2026 have been lowered to account for ongoing sales pressures on core products, although the increase in high-margin BD revenue and continuous cost reduction efforts are expected to improve the expense ratio [1] - The company announced an interim dividend of HKD 0.14 per share, with an expected full-year dividend of no less than HKD 0.28 per share, compared to HKD 0.26 per share last year [1] Market Outlook - The company’s prescription drug business faced continued pressure in Q2, but there may be opportunities for sequential improvement in the second half of the year [1] - Despite ongoing challenges from centralized procurement and hospital-end medical insurance fees, there is optimism for a recovery in performance in the second half of 2026-2027, driven by the resolution of these pressures and the positive impact of significant BD upfront payments [1]

Group 1 - The core business of the company is the production of finished drugs and raw materials, with a focus on innovative drugs targeting various therapeutic areas such as neurological diseases, oncology, infections, and cardiovascular diseases [1] - As of mid-2025, the company reported total revenue of 13.273 billion and a net profit of 2.548 billion [1] - The company has an international R&D team dedicated to the discovery, research, and development of small molecule targeted drugs, nanomedicines, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and biopharmaceuticals in the immunology field [1] Group 2 - On August 25, Zhuhai International maintained a buy rating for the company, raising the target price to 12.11 HKD [2]

Group 1 - The core viewpoint of the article highlights the recent stock performance of CSPC Pharmaceutical Group, which saw a decline of 2.75% to HKD 10.62 per share, with a trading volume of HKD 3.02 billion [1] - CSPC Pharmaceutical Group is a Hong Kong-listed pharmaceutical company focused on the production of finished drugs and active pharmaceutical ingredients, with a strategic emphasis on innovative drugs targeting various therapeutic areas including neurological diseases, oncology, anti-infection, and cardiovascular diseases [1] - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of HKD 70.15 billion and a net profit of HKD 14.78 billion [1] Group 2 - CSPC Pharmaceutical Group is scheduled to disclose its interim report for the fiscal year 2025 on August 22 [2]

Group 1 - The core viewpoint of the article highlights the performance and strategic focus of the company, CSPC Pharmaceutical Group, which has seen a stock price increase of 2.01% to HKD 10.66 per share with a trading volume of HKD 302 million as of August 15 [1] - CSPC Pharmaceutical Group is a Hong Kong-listed pharmaceutical company primarily engaged in the production of finished drugs and active pharmaceutical ingredients, with a core development strategy centered on innovative drugs targeting various therapeutic areas including neurological diseases, oncology, anti-infection, and cardiovascular diseases [1] - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of HKD 7.015 billion and a net profit of HKD 1.478 billion [1] Group 2 - The company is set to disclose its interim report for the fiscal year 2025 on August 22 [2]

Core Viewpoint - The stock price of CSPC Pharmaceutical Group Limited (01093) experienced a decline of 2.88% on August 7, trading at HKD 9.77 per share with a transaction volume of HKD 302 million [1]. Group 1: Company Overview - CSPC Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company primarily engaged in the production of finished drugs and active pharmaceutical ingredients, with a core development strategy focused on innovative drugs [1]. - The company has a strong product portfolio in the treatment areas of neurological diseases, oncology, anti-infection, and cardiovascular diseases [1]. - CSPC boasts an international R&D team dedicated to the discovery, research, and development of small molecule targeted drugs, nanomedicines, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and biopharmaceuticals in the immunology field [1]. Group 2: Financial Performance - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of HKD 7.015 billion and a net profit of HKD 1.478 billion [2].

Group 1 - The core viewpoint of the article highlights the performance and strategic focus of CSPC Pharmaceutical Group Limited, emphasizing its strong product portfolio in various therapeutic areas and its innovative drug development strategy [1][2][3] Group 2 - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of 7.015 billion yuan and a net profit of 1.478 billion yuan [2] - The company’s stock price increased by 2.07% to 9.86 yuan per share, with a trading volume of 0.852 billion yuan as of 11:40 AM on August 5 [1]